Filing Flows › Rhythm Pharmaceuticals (RYTM) › Takeover & LBO
Is Rhythm Pharmaceuticals (RYTM) a takeover target?
A leveraged buyout does not work for Rhythm Pharmaceuticals on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Historically 4.6% of companies with its figures were bought within a year (0.91× the average). Latest signal (2026-11-06): AstraZeneca stock weighs reported Rhythm takeover proposal.
Why a leveraged buyout does not fit
The buyout model needs Rhythm Pharmaceuticals' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
The odds, from history
Historically 4.6% of companies with its figures were bought within a year (0.91× the average). Its figures put it in decile 5 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Rumors and deal signals
- 2026-11-06 · news · AstraZeneca stock weighs reported Rhythm takeover proposal
Rhythm Pharmaceuticals' latest quarter
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
Is Rhythm Pharmaceuticals being acquired?
The latest signal on file is from 2026-11-06: AstraZeneca stock weighs reported Rhythm takeover proposal. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Rhythm Pharmaceuticals?
A leveraged buyout does not work for Rhythm Pharmaceuticals on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.